Clear Search

Showing 1 result for “Xiao S”.

June 2019

ヤヌスキナーゼ阻害薬が関節リウマチ患者の心血管イベントに及ぼすリスク: 無作為化試験のシステマティックレビューとメタ解析

Ann Rheum Dis. 2019 Aug;78(8):1048-1054.

Existing evidence from RCTs indicated no significant change in CV risk for JAK inhibitor (JAKinib) treated RA patients in a short-term perspective compared to placebo.Patients with RA have an elevated risk of CV morbidity and mortality, which cannot be fully explained by traditional CV risk factors. Reaching remission or LDA in order to reduce CV events (CVE) is encouraged in the current EULAR recommendations. JAKinibs and their roles in the modulation of CV risk remain undetermined. This study ...

もっと…